Mark Tebbe on ultradeep chemoproteomics and machine learning for covalent drug discovery

https://is1-ssl.mzstatic.com/image/thumb/Podcasts112/v4/95/bb/c0/95bbc02c-fcc9-6165-f53b-8357aa7b6f4e/mza_3772196312056908933.jpg/600x600bb.jpg

founders in biotech

Founders in biotech

14 episodes

2 days ago

Sharing the founder’s journey and scientific achievements to inspire the leaders of tomorrow. On each episode, the host Serghei Glinca, biotech entrepreneur and ecosystem builder, meets unconventional founders to talk about science, entrepreneurship, fundraising, and leadership. The shared lessons of the founder’s journey show a clear path how to take action and activate talents to start their own journey as founders. Serghei and guests also discuss practical perspectives and tools to motivate the scientific community to turn science into tangible impact.

Business

RSS

All content for founders in biotech is the property of Founders in biotech and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Business

https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/24063192/24063192-1655724126223-fc2b805003085.jpg

Mark Tebbe on ultradeep chemoproteomics and machine learning for covalent drug discovery

founders in biotech

30 minutes 45 seconds

3 years ago

Mark Tebbe on ultradeep chemoproteomics and machine learning for covalent drug discovery

Mark Tebbe started his career as an organic chemist and later had senior positions at Lilly. After 16 years of a successful career in pharma, Mark started his biotech journey. He has been leading drug discovery at multiple biotech companies including Forma Therapeutics, Quatet Medicine, and Quench Bio. Mark is also the co-inventor of Telaprevir. Telaprevir is an inhibitor of the serine protease NS3/4A of the hepatitis C virus. Mark is currently the CTO at Matchpoint Therapeutics, a company focused on development of precision covalent medicines.